PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research

Abstract 4779: IL-6/STAT3 signaling mediates MYB dysregulation in prostate cancer: Implications for aggressive disease progression and racial disparities

View Full Paper
Ask AI
Bookmark
Share

Authors

VVVinayaraj Ellu ValappilSAShashi AnandKVKunwar Somesh Vikramdeo

Discussion

Loading...

Member takes

Overview

Explores MYB dysregulation in prostate cancer, linking IL-6/STAT3 signaling to racial disparities in disease progression.

Key Points

  • To examine the molecular mechanisms of MYB dysregulation in prostate cancer and its implications for racial disparities in progression.
  • Measured serum IL-6 levels in Black prostate cancer patients.
  • Treated prostate cancer cell lines with IL-6 and assessed MYB expression changes.
  • Utilized IL-6 neutralizing antibody and STAT3 inhibitor to evaluate their effects on MYB expression.
  • Conducted chromatin immunoprecipitation (ChIP) analysis to assess STAT3 binding to MYB.
  • Examined the impact of MYB silencing and CDK9 inhibition on cell proliferation, migration, and invasion.
  • Elevated serum IL-6 levels were found in Black prostate cancer patients.
  • IL-6 treatment upregulated MYB expression in a dose- and time-dependent manner.
  • Pre-treatment with Tocilizumab and Stattic abolished IL-6-induced MYB upregulation.
  • Increased STAT3 binding to MYB correlated with enhanced CDK9 recruitment to regulate transcription.
  • MYB silencing or CDK9 inhibition significantly reduced IL-6-mediated cell proliferation, migration, and invasion.

Cite This Study

Valappil et al. (2026) studied this question.

synapsesocial.com/papers/69d1fcc0a79560c99a0a26d3https://doi.org/10.1158/1538-7445.am2026-4779
View Full Paper
Ask AI
Bookmark
Share